Aaron Ermel1, Yan Tong1, Phillip Tonui2, Omenge Orang'o2, Kapten Muthoka2, Nelson Wong1, Titus Manai3, Stephen Kiptoo4, Patrick J Loehrer1,5, Darron R Brown1. 1. 12250Indiana University School of Medicine, Indianapolis, IN, USA. 2. College of Health Sciences, School of Medicine, Department of Reproductive Health, 107853Moi University, Eldoret, Kenya. 3. 118971Maseno University, Maseno, Kenya. 4. Academic Model Providing Access to Healthcare (AMPATH) Cervical Cancer Screening Program, 107853Moi University, Eldoret, Kenya. 5. Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
Abstract
OBJECTIVE: A longitudinal study was conducted among women living with HIV in Kenya to determine if duration of anti-retroviral (ART) usage altered detection and persistence of oncogenic (high-risk) human papillomaviruses (HR-HPV). METHODS: Women living with HIV without cervical dysplasia were enrolled at a cervical cancer screening clinic. Three cervical swabs, HIV viral loads, and CD4 cell counts were obtained at enrollment and at two annual visits. HPV genotyping was performed on swabs (Roche Linear Array). Linear regression models assessed effects of ART duration on HR-HPV detection and persistence. RESULTS: Seventy-seven women, median age 38 years, completed three study visits and were included in the analysis. The mean time from HIV diagnosis to enrollment was 9.6 years (SD 3.9 years). The mean ART duration was 6.2 years (SD 3.1 years). Most women had undetectable HIV viral loads and CD4 cell counts above 500 cells/L. Each additional year of ART use reduced the likelihood of detection of HR-HPV by 10-15% and persistent detection of A9 HR-HPV by 20%. CONCLUSION: Among Kenyan women living with HIV, longer duration of ART use was associated with significantly reduced risk of all detection and persistent detection of HR-HPV.
OBJECTIVE: A longitudinal study was conducted among women living with HIV in Kenya to determine if duration of anti-retroviral (ART) usage altered detection and persistence of oncogenic (high-risk) human papillomaviruses (HR-HPV). METHODS: Women living with HIV without cervical dysplasia were enrolled at a cervical cancer screening clinic. Three cervical swabs, HIV viral loads, and CD4 cell counts were obtained at enrollment and at two annual visits. HPV genotyping was performed on swabs (Roche Linear Array). Linear regression models assessed effects of ART duration on HR-HPV detection and persistence. RESULTS: Seventy-seven women, median age 38 years, completed three study visits and were included in the analysis. The mean time from HIV diagnosis to enrollment was 9.6 years (SD 3.9 years). The mean ART duration was 6.2 years (SD 3.1 years). Most women had undetectable HIV viral loads and CD4 cell counts above 500 cells/L. Each additional year of ART use reduced the likelihood of detection of HR-HPV by 10-15% and persistent detection of A9 HR-HPV by 20%. CONCLUSION: Among Kenyan women living with HIV, longer duration of ART use was associated with significantly reduced risk of all detection and persistent detection of HR-HPV.
Entities:
Keywords:
HIV; Human papillomavirus; Kenya; anti-retroviral therapy; women
Authors: Hugo De Vuyst; Gathari Ndirangu; Manivasan Moodley; Vanessa Tenet; Benson Estambale; Chris J L M Meijer; Peter J F Snijders; Gary Clifford; Silvia Franceschi Journal: Int J Cancer Date: 2011-11-10 Impact factor: 7.396
Authors: Hugo De Vuyst; Michael H Chung; Iacopo Baussano; Nelly R Mugo; Vanessa Tenet; Folkert J van Kemenade; Farzana S Rana; Samah R Sakr; Chris J L M Meijer; Peter J F Snijders; Silvia Franceschi Journal: Int J Cancer Date: 2013-03-16 Impact factor: 7.396
Authors: Pangaja Paramsothy; Denise J Jamieson; Charles M Heilig; Paula C Schuman; Robert S Klein; Keerti V Shah; Anne M Rompalo; Susan Cu-Uvin; Ann Duerr Journal: Obstet Gynecol Date: 2009-01 Impact factor: 7.661
Authors: Y Tong; E Orang'o; M Nakalembe; P Tonui; P Itsura; K Muthoka; M Titus; S Kiptoo; A Mwangi; J Ong'echa; R Tonui; B Odongo; C Mpamani; B Rosen; A Moormann; S Cu-Uvin; J A Bailey; C I Oduor; A Ermel; C Yiannoutsos; B Musick; E Sang; A Ngeresa; G Banturaki; A Kiragga; J Zhang; Y Song; S Chintala; R Katzenellenbogen; P Loehrer; D R Brown Journal: Ann Med Date: 2022-12 Impact factor: 5.348